Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
XETRA:NVV1
Holding DE:NVV1?
Track your performance easily
NVV1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.33 - €23.93
Previous Close€7.57
Volume6.70K
Average Volume (3M)5.74K
Market Cap
€1.22B
Enterprise Value€978.17M
Total Cash (Recent Filing)$480.59M
Total Debt (Recent Filing)$229.33M
Price to Earnings (P/E)―
Beta3.00
Next Earnings
Mar 04, 2025EPS Estimate
-€0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,403,554
10 Day Avg. Volume13,109
30 Day Avg. Volume5,738
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-2.10
Price to Sales (P/S)62.83
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit4.60
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
€15.17Price Target Upside100.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Novavax News
Bulls Say, Bears Say
Bulls Say
Market CompetitivenessNovavax's high efficacy adjuvanted respiratory vaccine portfolio shows early signs of gaining market share against mRNA-based products.
Regulatory ProgressThe FDA has removed its clinical hold on Novavax' Investigational New Drug application, allowing the company to continue human studies with its COVID-19+Influenza Combination and stand-alone influenza vaccine candidates.
Strategic PartnershipsNovavax has signed a licensing agreement with Sanofi to co-commercialize COVID-19 vaccines and develop new combination vaccines, providing multiple strategic options.
Bears Say
Financial PerformanceManagement again lowered FY24 vaccine sales guidance to $175-225M (down from $275-375M) and total FY24 revs guidance to $650-700M (down from prior $700-800M).
Market ShareThe decreased sales guidance largely came from a relatively steady market share for Nuvaxovid of ~3% which fell below their expectations.
Regulatory ChallengesThe U.S. FDA has placed a clinical hold on Novavax's IND application for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates due to a reported serious adverse event.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.24% Insiders
11.45% Mutual Funds
13.51% Other Institutional Investors
56.87% Public Companies and
Individual Investors
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €3.33 and its highest was €23.93 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2025 which is in 102 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 12, 2024. The company reported -€0.721 earnings per share for the quarter, beating the consensus estimate of -€0.75 by €0.029.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -€0.57.
How many shares outstanding does Novavax have?
Novavax has 160,185,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.721 in its last earnings report, beating expectations of -€0.75. Following the earnings report the stock price went down -6.143%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 28M.
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.17 (100.48% Upside)
€15.17 (100.48% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVV1 Company Deck
---
NVV1 Earnings Call
Q3 2024
0:00 / 0:00
---
NVV1 Stock 12 Month Forecast
Average Price Target
€15.17
▲(100.48% Upside)
Technical Analysis
Best Analysts Covering NVV1
1 Year
1 Year Success Rate
20/36 ratings generated profit
1 Year Average Return
+152.76%
reiterated a buy rating 10 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +152.76% per trade.
---